MX2020003670A - Metodos para tratar infecciones bacterianas. - Google Patents

Metodos para tratar infecciones bacterianas.

Info

Publication number
MX2020003670A
MX2020003670A MX2020003670A MX2020003670A MX2020003670A MX 2020003670 A MX2020003670 A MX 2020003670A MX 2020003670 A MX2020003670 A MX 2020003670A MX 2020003670 A MX2020003670 A MX 2020003670A MX 2020003670 A MX2020003670 A MX 2020003670A
Authority
MX
Mexico
Prior art keywords
subject
methods
subjects
transplant
bone marrow
Prior art date
Application number
MX2020003670A
Other languages
English (en)
Inventor
Michael N Dudley
Elizabeth Alexander
Jeff Loutit
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65994826&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020003670(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of MX2020003670A publication Critical patent/MX2020003670A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos para tratar la infección bacteriana en sujetos inmunodeprimidos y sujetos con una o mas neoplasias subyacentes que incluyen la administración al sujeto de una combinación de meropenem y vaborbactam. Los sujetos adecuados a tratar pueden incluir un sujeto con un antecedente de leucemia o linfoma en curso, un sujeto que ha tenido un trasplante de órgano, trasplante de células madre, trasplante de medula ósea, o esplenectomia, un sujeto que recibe medicamentos inmunosupresores, un sujeto que recibe quimioterapia ablativa de medula ósea, un sujeto con neutropenia y un sujeto que padece o que ha padecido de una neoplasia.
MX2020003670A 2017-10-03 2018-10-01 Metodos para tratar infecciones bacterianas. MX2020003670A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762567702P 2017-10-03 2017-10-03
US201862657402P 2018-04-13 2018-04-13
PCT/US2018/053772 WO2019070591A1 (en) 2017-10-03 2018-10-01 METHODS OF TREATING BACTERIAL INFECTIONS

Publications (1)

Publication Number Publication Date
MX2020003670A true MX2020003670A (es) 2020-08-03

Family

ID=65994826

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003670A MX2020003670A (es) 2017-10-03 2018-10-01 Metodos para tratar infecciones bacterianas.

Country Status (16)

Country Link
US (3) US11376237B2 (es)
EP (1) EP3691652A4 (es)
JP (1) JP2020536092A (es)
KR (1) KR20200066664A (es)
CN (1) CN111432821A (es)
AU (1) AU2018345317B2 (es)
BR (1) BR112020006658A2 (es)
CA (1) CA3078238A1 (es)
CL (1) CL2020000892A1 (es)
JO (1) JOP20200075A1 (es)
MX (1) MX2020003670A (es)
MY (1) MY200934A (es)
PH (1) PH12020550249A1 (es)
SG (1) SG11202003009QA (es)
TW (2) TW201922241A (es)
WO (1) WO2019070591A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11376237B2 (en) 2017-10-03 2022-07-05 Melinta Subsidiary Corp. Methods of treating bacterial infections
EP4313033A4 (en) * 2021-03-24 2025-04-23 Trustees Of Tufts College BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101912363A (zh) 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
CA2807546C (en) 2010-08-10 2022-08-23 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN102188395B (zh) 2011-04-29 2012-12-05 石药集团中诺药业（石家庄）有限公司 一种更稳定的美罗培南注射剂及其制备方法
CN102335136B (zh) 2011-08-02 2013-06-12 天津市嵩锐医药科技有限公司 一种供注射用美罗培南药物组合物及其制备方法
CN102335137B (zh) 2011-08-02 2013-06-12 天津市嵩锐医药科技有限公司 一种含美罗培南的药物组合物
CN102525961B (zh) 2012-01-17 2013-02-13 山东罗欣药业股份有限公司 美罗培南组合物注射用粉针剂
US10561675B2 (en) * 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN103570718B (zh) 2012-07-31 2016-06-29 深圳市海滨制药有限公司 一种美罗培南原料药、其制备方法及包含其的药物组合物
RU2675847C2 (ru) 2013-05-28 2018-12-25 Морфохем Акциенгезельшафт Фюр Комбинаторише Хеми Комбинированные терапевтические средства, содержащие оксазолидинон-хинолоны, предназначенные для лечения бактериальных инфекций
WO2016172208A1 (en) 2015-04-24 2016-10-27 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
CN108289896B (zh) 2015-07-09 2022-03-01 华盛顿大学 抗菌药物组合的组合物和使用方法
US9949995B2 (en) 2015-09-04 2018-04-24 Case Western Reserve University Compositions and methods of treating of bacterial infections with β-lactamase inhibitors
JP7436206B2 (ja) 2017-01-09 2024-02-21 レンペックス・ファーマシューティカルズ・インコーポレイテッド 細菌感染症を処置する方法
US11376237B2 (en) * 2017-10-03 2022-07-05 Melinta Subsidiary Corp. Methods of treating bacterial infections

Also Published As

Publication number Publication date
AU2018345317B2 (en) 2024-10-24
CA3078238A1 (en) 2019-04-11
EP3691652A1 (en) 2020-08-12
US11376237B2 (en) 2022-07-05
JP2020536092A (ja) 2020-12-10
US20200297695A1 (en) 2020-09-24
JOP20200075A1 (ar) 2020-04-30
AU2018345317A1 (en) 2020-05-07
PH12020550249A1 (en) 2021-02-15
KR20200066664A (ko) 2020-06-10
EP3691652A4 (en) 2021-07-07
MY200934A (en) 2024-01-24
US20220288024A1 (en) 2022-09-15
CN111432821A (zh) 2020-07-17
CL2020000892A1 (es) 2020-10-23
BR112020006658A2 (pt) 2020-09-24
SG11202003009QA (en) 2020-04-29
WO2019070591A1 (en) 2019-04-11
US12533342B2 (en) 2026-01-27
US20260102374A1 (en) 2026-04-16
TW202400146A (zh) 2024-01-01
TW201922241A (zh) 2019-06-16

Similar Documents

Publication Publication Date Title
MX2024008677A (es) Conjugados de camptotecina.
PH12020551923A1 (en) Methods and compositions for treating cancer
CL2022001752A1 (es) Compuesto de piridazinil-tiazolcarboxamida
EP4599848A3 (en) Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
MX2022001075A (es) Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
CY1125242T1 (el) Κυτταροκαλλιεργεια
NZ742208A (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
BR112017006113A2 (pt) combinações sinérgicas de auristatina
EP4389209A3 (en) Fecal microbiota composition, for use in reducing treatment-induced inflammation
ES2525137B1 (es) Agentes para tratar el mieloma múltiple
PH12017501300A1 (en) Novel iodophor composition and methods of use
WO2018217710A8 (en) Micro-nanobubble solutions for tissue preservation and generation thereof
WO2018009528A8 (en) Combination cancer immunotherapies with arginine depletion agents
CL2018001913A1 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
MX393900B (es) Uso de gaboxadol en el tratamiento de tinnitus.
CO2020006907A2 (es) Péptidos antimicrobianos y métodos para usarlos
CO2018008449A2 (es) Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CL2018001911A1 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CL2019001918A1 (es) Métodos para tratar infecciones bacterianas.
MX2020003670A (es) Metodos para tratar infecciones bacterianas.
WO2020072519A8 (en) Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy
MX2018002816A (es) Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t.
CA3011003A1 (en) Bacterial ghosts for the treatment of cancer
MX2024005589A (es) Combinaciones de lurbinectedina y atezolizumab.
GEAP202215466A (en) Topical formulations comprising strontium and methylsulfonylmethane (msm) and methods of treatment